MA30345B1 - Formulation d'anticorps monoclonal humain anti-igf-1r - Google Patents
Formulation d'anticorps monoclonal humain anti-igf-1rInfo
- Publication number
- MA30345B1 MA30345B1 MA31308A MA31308A MA30345B1 MA 30345 B1 MA30345 B1 MA 30345B1 MA 31308 A MA31308 A MA 31308A MA 31308 A MA31308 A MA 31308A MA 30345 B1 MA30345 B1 MA 30345B1
- Authority
- MA
- Morocco
- Prior art keywords
- igf
- monoclonal antibody
- human monoclonal
- antibody formulation
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06111848 | 2006-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30345B1 true MA30345B1 (fr) | 2009-04-01 |
Family
ID=37025222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31308A MA30345B1 (fr) | 2006-03-28 | 2008-10-20 | Formulation d'anticorps monoclonal humain anti-igf-1r |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1998806A1 (es) |
JP (1) | JP2009531371A (es) |
KR (1) | KR20080104160A (es) |
CN (1) | CN101410137A (es) |
AR (1) | AR060130A1 (es) |
AU (1) | AU2007229554A1 (es) |
BR (1) | BRPI0709229A2 (es) |
CA (1) | CA2647111A1 (es) |
CL (1) | CL2007000797A1 (es) |
CR (1) | CR10295A (es) |
EC (1) | ECSP088778A (es) |
IL (1) | IL193904A0 (es) |
MA (1) | MA30345B1 (es) |
MX (1) | MX2008012295A (es) |
NO (1) | NO20083895L (es) |
RU (1) | RU2008142359A (es) |
TW (1) | TW200815029A (es) |
WO (1) | WO2007110339A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20081477A1 (es) * | 2006-12-11 | 2008-10-18 | Hoffmann La Roche | Formulacion liofilizada mab abeta |
GB0702888D0 (en) * | 2007-02-14 | 2007-03-28 | Glaxo Group Ltd | Novel Antibodies |
UA96473C2 (ru) * | 2007-03-22 | 2011-11-10 | Имклоун Ллк | Жидкая стойкая композиция, которая содержит антитело imc-а12 |
CN101687038A (zh) * | 2007-07-10 | 2010-03-31 | 霍夫曼-拉罗奇有限公司 | 新型制剂 |
US20100249384A1 (en) * | 2007-11-29 | 2010-09-30 | Stefan Hepbildikler | Immunoglobulin aggregates |
UA101487C2 (en) * | 2007-12-21 | 2013-04-10 | Ф. Хоффманн-Ля Рош Аг | Humanized b-ly1 antibody formulation |
WO2010069858A1 (en) * | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
US20110158987A1 (en) * | 2009-12-29 | 2011-06-30 | F. Hoffmann-Laroche Ag | Novel antibody formulation |
EP2575761A1 (en) * | 2010-05-28 | 2013-04-10 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
PT2691112T (pt) | 2011-03-31 | 2018-07-10 | Merck Sharp & Dohme | Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados |
CN102363040B (zh) * | 2011-10-21 | 2013-05-01 | 北京锐瑟科技有限公司 | 用于粘膜组织的抗微生物肽制剂 |
SG11201508911PA (en) | 2013-04-29 | 2015-11-27 | Hoffmann La Roche | Human fcrn-binding modified antibodies and methods of use |
CN103505729B (zh) * | 2013-05-24 | 2015-10-28 | 华北制药集团新药研究开发有限责任公司 | 一种稳定的狂犬病毒人源抗体组合制剂 |
CN104707146B (zh) * | 2013-12-16 | 2019-04-16 | 浙江海正药业股份有限公司 | 一种含有阿达木单抗的药物组合物 |
JP6778110B2 (ja) | 2014-01-15 | 2020-10-28 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 改善されたプロテインA結合を有するFc領域バリアント |
JP6707469B2 (ja) * | 2014-05-28 | 2020-06-10 | ノノ インコーポレイテッド | アセチル化スカベンジャーを含むTat−NR2B9cの凍結乾燥製剤 |
AR102198A1 (es) * | 2014-10-09 | 2017-02-08 | Regeneron Pharma | Proceso para reducir partículas subvisibles en una formulación farmacéutica |
RS62986B1 (sr) | 2015-06-24 | 2022-03-31 | Hoffmann La Roche | Antitela na transferinski receptor sa prilagođenim afinitetom |
UA124259C2 (uk) * | 2015-09-28 | 2021-08-18 | Сужоу Санкадіа Байофармасьютікалз Ко., Лтд. | Фармацевтичне одержання стабільного анти-pd-1 антитіла та його застосування в медицині |
TWI819458B (zh) | 2015-10-02 | 2023-10-21 | 瑞士商赫孚孟拉羅股份公司 | 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
CN106199007B (zh) * | 2016-08-03 | 2017-04-05 | 烟台普罗吉生物科技发展有限公司 | 蛋白保护剂 |
EA201990317A1 (ru) | 2016-08-16 | 2019-07-31 | Ридженерон Фармасьютикалз, Инк. | Способы определения количества индивидуальных антител из смеси |
US10613063B2 (en) | 2016-10-25 | 2020-04-07 | Regeneron Pharmaceuticals, Inc. | Methods and systems for chromatography data analysis |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
MX2019013072A (es) | 2017-05-02 | 2019-12-16 | Merck Sharp & Dohme | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1. |
TW202005694A (zh) | 2018-07-02 | 2020-02-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
CN114324882B (zh) * | 2020-10-12 | 2022-12-27 | 广东菲鹏生物有限公司 | 蛋白稳定剂及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0999853T3 (da) * | 1997-06-13 | 2003-04-22 | Genentech Inc | Stabiliseret antostofformulering |
DK1399483T3 (da) * | 2001-01-05 | 2010-08-02 | Pfizer | Antistoffer til insulinlignende vækstfaktorrecptor I |
EP1409018B1 (en) * | 2001-07-25 | 2010-01-06 | Facet Biotech Corporation | Stable lyophilized pharmaceutical formulation the igg antibody daclizumab |
CA2519113C (en) * | 2003-04-02 | 2012-06-05 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
PT1610820E (pt) * | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
US7579157B2 (en) * | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
ES2351395T3 (es) * | 2003-08-13 | 2011-02-04 | Pfizer Products Inc. | Anticuerpos humanos modificados anti-igf-1r. |
-
2007
- 2007-03-19 RU RU2008142359/15A patent/RU2008142359A/ru not_active Application Discontinuation
- 2007-03-19 JP JP2009502016A patent/JP2009531371A/ja active Pending
- 2007-03-19 MX MX2008012295A patent/MX2008012295A/es active IP Right Grant
- 2007-03-19 CA CA002647111A patent/CA2647111A1/en not_active Abandoned
- 2007-03-19 EP EP07727047A patent/EP1998806A1/en not_active Withdrawn
- 2007-03-19 CN CNA2007800114320A patent/CN101410137A/zh active Pending
- 2007-03-19 AU AU2007229554A patent/AU2007229554A1/en not_active Abandoned
- 2007-03-19 KR KR1020087023673A patent/KR20080104160A/ko not_active Application Discontinuation
- 2007-03-19 BR BRPI0709229-6A patent/BRPI0709229A2/pt not_active IP Right Cessation
- 2007-03-19 WO PCT/EP2007/052569 patent/WO2007110339A1/en active Application Filing
- 2007-03-26 CL CL2007000797A patent/CL2007000797A1/es unknown
- 2007-03-26 TW TW096110388A patent/TW200815029A/zh unknown
- 2007-03-26 AR ARP070101241A patent/AR060130A1/es not_active Application Discontinuation
-
2008
- 2008-09-04 IL IL193904A patent/IL193904A0/en unknown
- 2008-09-11 NO NO20083895A patent/NO20083895L/no not_active Application Discontinuation
- 2008-09-17 CR CR10295A patent/CR10295A/es not_active Application Discontinuation
- 2008-09-26 EC EC2008008778A patent/ECSP088778A/es unknown
- 2008-10-20 MA MA31308A patent/MA30345B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
TW200815029A (en) | 2008-04-01 |
BRPI0709229A2 (pt) | 2011-06-28 |
CR10295A (es) | 2008-10-06 |
JP2009531371A (ja) | 2009-09-03 |
IL193904A0 (en) | 2011-08-01 |
NO20083895L (no) | 2008-10-24 |
CL2007000797A1 (es) | 2008-01-25 |
AR060130A1 (es) | 2008-05-28 |
KR20080104160A (ko) | 2008-12-01 |
CA2647111A1 (en) | 2007-10-04 |
AU2007229554A1 (en) | 2007-10-04 |
CN101410137A (zh) | 2009-04-15 |
WO2007110339A1 (en) | 2007-10-04 |
ECSP088778A (es) | 2008-10-31 |
EP1998806A1 (en) | 2008-12-10 |
RU2008142359A (ru) | 2010-05-10 |
MX2008012295A (es) | 2008-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30345B1 (fr) | Formulation d'anticorps monoclonal humain anti-igf-1r | |
MA31984B1 (fr) | Formulation d'anticorps | |
MA29369B1 (fr) | Dosage fixe d'anticorps anti-her | |
MA30497B1 (fr) | Anticorps et immunco-conjugues, et leurs utilisations. | |
MA31502B1 (fr) | Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation | |
SG196835A1 (en) | Human anti-b7rp1 neutralizing antibodies | |
MA32099B1 (fr) | Composition comprenant un anticorps se liant au domaine ii de her2 et variantes acides de celle-ci | |
MA33198B1 (fr) | Anticorps anti-her di-spécifiques | |
MA30353B1 (fr) | Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes. | |
MA31231B1 (fr) | Anticorps anti-robo4 et utilisations de ceux-ci | |
MA30910B1 (fr) | Anticorps et immunoconjugues, et leurs utilisations | |
MA30945B1 (fr) | Anticorps anti-tat226 et immunoconjugués | |
MA34524B1 (fr) | Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3) | |
EA200601670A1 (ru) | Конъюгаты гидроксиалкилкрахмала и белка | |
BR0316670A (pt) | Anticorpos quiméricos e humanizados para integrina (alfa)5ß1 que modulam a angiogênese | |
MA30922B1 (fr) | Anticorps d'agonistes de trkb et leurs utilisations | |
EA200800812A1 (ru) | Композиции антитела против cd3 | |
JO3000B1 (ar) | مركبات أجسام مضادة . | |
MA33537B1 (fr) | Anticorps anti-cdcp1 humanisés | |
MA33402B1 (fr) | Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps | |
ATE391174T1 (de) | Modifizierter tpo-agonisten antikörper | |
HK1071586A1 (en) | Transplant acceptance inducing cells of monocytic origin and their preparation and use | |
ATE552276T1 (de) | Modifizierter anti-cd52-antikörper | |
AR058085A1 (es) | Sal de dihidrogeno fosfato de un antagonista del receptor de prostaglandina d2. composiciones farmaceuticas. | |
MA50752A (fr) | Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation |